AR and triple-negative breast carcinoma: In triple negative breast cancer (TNBC), the luminal androgen receptor (LAR) subtype, characterized by the expression of androgen receptor, is associated with better prognosis, less chemotherapy responsiveness, and lower pathologic complete response after neoadjuvant treatment10.